CD47 is overexpressed by multiple tumor types and functions as an important immune escape mechanism. CD47-overexpressing tumor cells communicate a “don’t eat me” signal (macrophage checkpoint), which prevents them from being engulfed and eliminated by macrophages. Because of the number of cancers that express CD47, it is a target with broad therapeutic potential.

SRF231 blocks the CD47 signal and makes tumor cells vulnerable to macrophage attack. Preclinical studies of SRF231 have shown that it binds with high affinity to CD47, stimulates phagocytosis and the killing of cancer cells in vitro and has potent anti-tumor activity preclinically, both as monotherapy and in combination settings. SRF231 does not induce detectable hemagglutination or phagocytosis of red blood cells, a potentially important safety advantage.

Surface has initiated a Phase I clinical trial that is currently evaluating the safety and tolerability of SRF231 with the goal of establishing a recommended dose for further study in patients with cancer. For more information about our clinical trials, visit www.clinicaltrials.gov.

Expanded access, or compassionate use, is the use of an investigational medicine prior to regulatory approval and outside of a clinical trial.

Surface Oncology does not currently have an expanded access program or compassionate use program for any of our investigational products.

We understand that for patients with serious diseases such as cancer, waiting for an approved treatment can be difficult. We believe that devoting ourselves to current and future clinical trial programs provides the best path to meet our goal of providing therapeutics to patients with cancer.

We encourage you to speak with your physician about options that may be right for you.